Evidence map›Paper›PMID 34706362›Full record

ArticleUrologia internationalis2023

Expression of FOXA1 Is Associated with the Tumor-Infiltrating M2 Macrophage, Cytotoxic T Lymphocyte, and Effect of Chemotherapy in Bladder Cancer.

Yiduo Wang, Huan Qu, Bin Xu, Jianping Wu, Kai Lu, Chunhui Liu, Shuqiu Chen, Ming Chen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologia internationalis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yiduo WangDepartment of Urology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China, wangyiduo2013@sina.com.
Huan QuHealth Management Center, Zhongda Hospital, Southeast University, Nanjing, China.
Bin XuDepartment of Urology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Jianping WuDepartment of Urology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Kai LuDepartment of Urology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Chunhui LiuDepartment of Urology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Shuqiu ChenDepartment of Urology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Ming ChenDepartment of Urology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Zhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCisplatin-containing combination chemotherapy has been the standard of care since the late 1980s, but the response rate is <50%. Studies have shown that the efficiency of chemotherapy differs among molecular subtypes of bladder cancer. In this study, we aimed to correlate FOXA1, a marker for differentiation of the basal and luminal subtypes, with tumor immune cell infiltration and the effect of chemotherapy in bladder cancer. MATERIALS AND

methodsEighty-three patients with bladder cancer treated with chemotherapy were reviewed. Clinicopathological variables for each case were recorded. FOXA1, M2 tumor-associated macrophage (TAM), dendritic cell (DC), and cytotoxic T lymphocyte (CTL) were examined by immunohistochemistry. The relationship between FOXA1, immune cell infiltration, and clinical response to chemotherapy was assessed.

resultsThe overall objective response rate was 34%. The objective response rate for tumors with lower FOXA1 expression was 58% and for tumors with higher FOXA1 expression was 12%. Tumors with infiltrated M2 TAM proportion <3% had a higher objective response rate compared with infiltrated M2 TAM proportion >3% tumors (46% vs. 21%, p = 0.02). Tumors with infiltrated CTL proportion >5% had a higher objective response rate compared with infiltrated CTL proportion <5% tumors (50% vs. 17%, p = 0.002). DCs showed no significant differences. We found that the objective response rate for tumors with lower FOXA1 expression, proportion <3% M2 TAM infiltration, and proportion >5% CTL infiltration is 82%. Lower FOXA1 expression was associated with low M2 TAM infiltration and high CTL infiltration.

conclusionsThus, we showed that in patients with bladder cancer who received chemotherapy, the higher clinical response rate is associated with low FOXA1 expression, low M2 TAM infiltration, and high CTL infiltration.

Indexed as

Hepatocyte Nuclear Factor 3-alphaT-Lymphocytes, CytotoxicUrinary Bladder NeoplasmsCisplatinHumansImmunohistochemistryMacrophagesCisplatinFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaBladder cancerChemotherapyCytotoxic T lymphocyteFOXA1M2 tumor-associated macrophage

Identifiers

PMID34706362
PMCPMC9909707
OpenAlexW3210554535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.